Annexure - I

MSKC & Associates LLP
Chartered Accountants

602, Floor 6, Raheja Titanium
Western Express Highway, Geetanjali Railway Colony
Ram Nagar, Goregaon (E) Mumbai 400063, INDIA

Independent Auditor's Review Report on standalone unaudited financial results of Wockhardt Limited for the quarter ended June 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Wockhardt Limited (hereinafter referred to as 'the Company') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K C & Associates LLP
Chartered Accountants
ICAI Firm Registration Number: 001595S/S000168

Bhavik L.Shah
Partner
Membership No.: 122071
UDIN: 26122071OLXIBA4826

M S K C & ASSOCIATES LLP Chartered Accountants

Place: Mumbai
Date: August 10, 2026

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
CIN:L24230MH1999PLC120720
Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com ,

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Rs in Crore except per share data)

	PARTICULARS	3 MONTHS ENDED 30/06/2026	3 MONTHS ENDED 31/03/2026	3 MONTHS ENDED 30/06/2025	YEAR ENDED 31/03/2026
	(Refer notes below)	Unaudited	Audited (Refer note 2)	Unaudited	Audited
1	**Income**				
	(a) Revenue from operations	561	516	413	1,739
	(b) Other income	33	55	25	137
	Total income	**594**	**571**	**438**	**1,876**
2	**Expenses**				
	(a) Cost of materials consumed	106	79	74	309
	(b) Purchase of stock-in-trade	57	40	39	198
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	0.08	1	(0.05)	(92)
	(d) Employee benefits expense	85	79	68	313
	(e) Finance costs	43	41	41	176
	(f) Depreciation and amortisation expense	41	43	46	186
	(g) Other expenses	155	156	101	494
	Total expenses	**487**	**439**	**369**	**1,584**
3	**Profit before exceptional items and tax (1-2)**	**107**	**132**	**69**	**292**
4	Exceptional items- credit	-	35	-	25
5	**Profit before tax (3 ± 4)**	**107**	**167**	**69**	**317**
6	Tax expense:				
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
7	**Net Profit after tax (5 ± 6)**	**107**	**167**	**69**	**317**
8	Other Comprehensive Income:				
	i) Items that will not be reclassified to Profit or Loss - credit/(charge) (consisting of re-measurement of net defined benefit liability)	0.08	1	(0.23)	0.08
	ii) Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-
	iii) Other Comprehensive Income (net of tax) (8i ± 8ii)	0.08	1	(0.23)	0.08
9	**Total Comprehensive Income (7 ± 8(iii))**	**107**	**168**	**69**	**317**
10	Paid-up equity share capital (face value of Rs. 5/- each)	81	81	81	81
11	Other Equity excluding Revaluation Reserves as per balance sheet				3,003
12	Earnings per share (face value of Rs. 5/- each) (*not annualised)				
	(a) Basic (Rs.)	6.62*	10.29*	4.25*	19.54
	(b) Diluted (Rs.)	6.61*	10.28*	4.25*	19.52

M S K C & ASSOCIATES LLP Chartered Accountants

WOCKHARDT LTD. MUMBAI

Notes to Standalone results :-

1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The results have been subjected to limited review by the Statutory Auditors of the Company.

2) Figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures of the full financial year and the reviewed published figures upto the third quarter of the financial year 2025-26.

3) The Company is exclusively into Pharmaceutical business segment.

Mumbai
Date: August 10, 2026

MSKC & ASSOCIATES LLP Chartered Accountants

WOCKHARDT LTD. MUMBAI

FOR WOCKHARDT LIMITED

H.F KHORAKIWALA
CHAIRMAN
DIN:00045608

MSKC & Associates LLP
Chartered Accountants

602, Floor 6, Raheja Titanium
Western Express Highway, Geetanjali Railway Colony
Ram Nagar, Goregaon (E) Mumbai 400063, INDIA

Independent Auditor's Review Report on consolidated unaudited financial results of Wockhardt Limited for the quarter ended June 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Wockhardt Limited (hereinafter referred to as 'the Company' or 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Wockhardt UK Holdings Limited	Wholly Owned Subsidiary
2	CP Pharmaceuticals Limited	Step-Down Subsidiary
3	CP Pharma (Schweiz) AG	Step-Down Subsidiary
4	Wallis Group Limited	Step-Down Subsidiary
5	The Wallis Laboratory Limited	Step-Down Subsidiary
6	Wockhardt Farmaceutica Do Brasil Ltda	Step-Down Subsidiary

MSKC & ASSOCIATES LLP Chartered Accountants

7	Wallis Licensing Limited	Step-Down Subsidiary
8	Wockhardt Infrastructure Development Limited	Wholly Owned Subsidiary
9	Z&Z Services GmbH	Step-Down Subsidiary
10	Wockhardt Europe Limited	Wholly Owned Subsidiary
11	Wockhardt Nigeria Limited	Step-Down Subsidiary
12	Wockhardt UK Limited	Step-Down Subsidiary
13	Wockpharma Ireland Limited	Step-Down Subsidiary
14	Pinewood Laboratories Limited	Step-Down Subsidiary
15	Pinewood Healthcare Limited	Step-Down Subsidiary
16	Wockhardt Holding Corp.	Step-Down Subsidiary
17	MGP Inc.	Step-Down Subsidiary
18	Wockhardt Farmaceutica SA DE CV	Step-Down Subsidiary
19	Wockhardt Services SA DE CV	Step-Down Subsidiary
20	Wockhardt Bio AG	Subsidiary
21	Wockhardt Bio (R) LLC	Step-Down Subsidiary
22	Wockhardt Bio Pty Limited	Step-Down Subsidiary
23	Wockhardt Medicines Limited	Wholly Owned Subsidiary
24	Wockhardt Bioscience Limited (Formerly, Wockhardt Bionova Limited)	Wholly Owned Subsidiary
25	Wockhardt Antibiotics (Ireland) Limited	Step-Down Subsidiary
26	Wockhardt Suisse AG	Step-Down Subsidiary
27	Wockhardt Suisse USA Holding Corporation	Step-Down Subsidiary
28	Wockhardt Suisse USA LLC	Step-Down Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

M S K C & ASSOCIATES LLP ★ Chartered Accountants ★

6. We did not review the interim financial information of 5 subsidiaries included in the Statement, whose interim financial information (before Consolidation Adjustments) reflects total revenues of Rs. 777 crores, total net loss after tax of Rs. 2 crores and total comprehensive loss of Rs. 2 crores, for the quarter ended June 30, 2026. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

7. The Statement includes the interim financial information of 18 subsidiaries which have not been reviewed by their auditors, whose interim financial information (before Consolidation Adjustments) reflects total revenue of Rs. 46 crores, total net profit after tax of Rs. 10 crores and total comprehensive income of Rs. 10 crores for the quarter ended June 30, 2026. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

For M S K C & Associates LLP
Chartered Accountants
ICAI Firm Registration Number: 001595S/S000168

Bhavik L. Shah
Partner
Membership No.: 122071
UDIN: 26122071SCLAZO9534

Place: Mumbai
Date: August 10, 2026

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CIN: L24230MH1999PLC120720

Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

(Rs. In Crore except per share data)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

	PARTICULARS	3 MONTHS ENDED 30/06/2026	3 MONTHS ENDED 31/03/2026	3 MONTHS ENDED 30/06/2025	YEAR ENDED 31/03/2026
	(Refer Notes Below)	Unaudited	Audited (Refer note 4)	Unaudited	Audited
1	**Income**				
	(a) Revenue from operations	929	965	738	3,373
	(b) Other income	31	45	20	111
	Total income	**960**	**1,010**	**758**	**3,484**
2	**Expenses**				
	(a) Cost of materials consumed	233	177	168	674
	(b) Purchase of stock-in-trade	109	156	140	586
	(c) Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(22)	(15)	(44)	(128)
	(d) Employee benefits expense	203	187	171	725
	(e) Finance costs	52	50	48	213
	(f) Depreciation and amortisation expense	55	53	56	227
	(g) Exchange fluctuation loss, net	(4)	(29)	29	(22)
	(h) Other expenses	218	264	202	886
	Total expenses	**844**	**843**	**770**	**3,161**
3	**Profit /(Loss) before exceptional items and tax (1-2)**	**116**	**167**	**(12)**	**323**
4	Exceptional items- charge (Note 4)	-	22	(97)	(85)
5	**Profit /(Loss) after exceptional items and before tax (3 ± 4)**	**116**	**189**	**(109)**	**238**
6	Tax expense:				
	Current tax - charge	7	5	4	18
	Deferred tax - charge/ (credit) - (Net)	2	20	(5)	21
7	**Net Profit /(Loss) after tax (5 ± 6)**	**107**	**164**	**(108)**	**199**
	Attributable to :				
	Equity shareholders of the Company	106	166	(90)	213
	Non - Controlling Interest	1	(2)	(18)	(14)
8	**Other Comprehensive Income**				
	(a) Items that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset)	0.08	71	(0.23)	70
	(b) Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge)	-	-	-	-
	(c) Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations)	14	79	148	349
	(d) Other Comprehensive Income (net of tax) (a ± b ± c)	14	150	148	419
9	**Total Comprehensive Income (7 ± 8 (d))**	**121**	**314**	**40**	**618**
	Other Comprehensive Income attributable to :				
	Equity shareholders of the Company	10	121	139	368
	Non - Controlling Interest	4	29	9	51
		14	**150**	**148**	**419**
	Total Comprehensive Income attributable to :				
	Equity shareholders of the Company	116	287	49	581
	Non - Controlling Interest	5	27	(9)	37
		121	**314**	**40**	**618**
10	Paid-up equity share capital (face value of Rs. 5/- each)	81	81	81	81
11	Other Equity excluding Revaluation Reserves as per Balance Sheet				4,859
12	Earnings per equity share (face value of Rs. 5/- each) (*not annualised)				
	(a) Basic (Rs.)	6.55*	10.23*	(5.53)*	13.12
	(b) Diluted (Rs.)	6.55*	10.22*	(5.53)*	13.10

M S K C & ASSOCIATES LLP * Chartered Accountants *

WOCKHARDT LTD. * MUMBAI *

Notes To Consolidated Results:-

1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The results have been subjected to limited review by the Statutory Auditors of the Company.

2) The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 - "Consolidated Financial Statements".

3) **Key Financials on Standalone basis:**

(Rs. In Crore)

PARTICULARS	3 MONTHS ENDED 30/06/2026	3 MONTHS ENDED 31/03/2026	3 MONTHS ENDED 30/06/2025	YEAR ENDED 31/03/2026
	Unaudited	Audited (Refer note 4)	Unaudited	Audited
Total Income	594	571	438	1,876
Profit (Loss) before tax	107	167	69	317
Profit (Loss) after tax	107	167	69	317

Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

4) Figures for the quarter ended March 31, 2026 is the balancing figure between the audited figures of the full financial year and the reviewed figures upto the third quarter of financial year 2025-26.

5) The Group is exclusively into Pharmaceutical business segment.

6) For List of Subsidiaries as on June 30, 2026 please refer Annexure.

Mumbai
Date: August 10, 2026

M S K C & ASSOCIATES LLP Chartered Accountants

WOCKHARDT LTD. MUMBAI

FOR WOCKHARDT LIMITED

H F KHORAKIWALA
CHAIRMAN
DIN: 00045608

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

List of Subsidiaries as on June 30, 2026

1 Wockhardt UK Holdings Limited
2 CP Pharmaceuticals Limited
3 CP Pharma (Schweiz) AG
4 Wallis Group Limited
5 The Wallis Laboratory Limited
6 Wockhardt Farmaceutica Do Brasil Ltda
7 Wallis Licensing Limited
8 Wockhardt Infrastructure Development Limited
9 Z & Z Services GmbH
10 Wockhardt Europe Limited
11 Wockhardt Nigeria Limited
12 Wockhardt UK Limited
13 Wockpharma Ireland Limited
14 Pinewood Laboratories Limited
15 Pinewood Healthcare Limited
16 Wockhardt Holding Corp.
17 MGP Inc.
18 Wockhardt Farmaceutica SA DE CV
19 Wockhardt Services SA DE CV
20 Wockhardt Bio AG
21 Wockhardt Bio (R) LLC
22 Wockhardt Bio Pty Limited
23 Wockhardt Medicines Limited
24 Wockhardt Bioscience Limited (Formerly, Wockhardt Bionova Limited)
25 Wockhardt Antibiotics (Ireland) Limited
26 Wockhardt Suisse AG
27 Wockhardt Suisse USA Holding Corporation
28 Wockhardt Suisse USA LLC

MSKC & ASSOCIATES LLP Chartered Accountants

WOCKHARDT LTD. MUMBAI